Xenetic Biosciences (XBIO) Long-Term Deferred Tax (2014 - 2025)
Xenetic Biosciences' (XBIO) quarterly Long-Term Deferred Tax came in at $39.8 million in Q4 2025, up 538501.14% on a QoQ basis from $7388.0 in Q4 2021.
Xenetic Biosciences (XBIO) Long-Term Deferred Tax (2014 - 2025) Analysis & Trends
Xenetic Biosciences (XBIO) has 8 years of Long-Term Deferred Tax data on file, last reported at $39.8 million in Q4 2025.
- Quarterly Long-Term Deferred Tax changed N/A year-over-year to $39.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $39.8 million (changed N/A YoY) and the FY2025 annual result came in at $39.8 million, changed N/A from the prior year.
- Long-Term Deferred Tax grew to $39.8 million in Q4 2025, from $7388.0 in the prior quarter.
- In the past five years, Long-Term Deferred Tax ranged from a high of $39.8 million in Q4 2025 to a low of $7388.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Xenetic Biosciences | 8.01 Mn | 1.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 39.79 Mn |
| Dec 31, 2021 | 7,388.00 |
| Dec 31, 2020 | 17,082.00 |
| Dec 31, 2019 | 5,475.00 |
| Dec 31, 2017 | 22.76 Mn |
| Dec 31, 2016 | 21.50 Mn |
| Dec 31, 2015 | 15.90 Mn |
| Sep 30, 2015 | 17.20 Mn |
| Jun 30, 2015 | 15.10 Mn |
| Mar 31, 2015 | 14.60 Mn |
| Dec 31, 2014 | 13.77 Mn |